Symbols / CRSP $47.04 +0.23%
CRSP Chart
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.52B |
| Enterprise Value | 2.74B | Income | -581.60M | Sales | 3.51M |
| Book/sh | 20.04 | Cash/sh | 20.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -11.20 | PEG | — |
| P/S | 1286.37 | P/B | 2.35 | P/C | — |
| EV/EBITDA | -4.99 | EV/Sales | 779.89 | Quick Ratio | 13.25 |
| Current Ratio | 13.32 | Debt/Eq | 10.76 | LT Debt/Eq | — |
| EPS (ttm) | -6.47 | EPS next Y | -4.20 | EPS Growth | — |
| Revenue Growth | -97.60% | Earnings | 2026-05-11 | ROA | -15.76% |
| ROE | -30.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -179.12% | Profit Margin | 0.00% | Shs Outstand | 95.99M |
| Shs Float | 95.58M | Short Float | 25.20% | Short Ratio | 12.91 |
| Short Interest | — | 52W High | 78.48 | 52W Low | 30.04 |
| Beta | 1.74 | Avg Volume | 1.92M | Volume | 708.55K |
| Target Price | $83.96 | Recom | Buy | Prev Close | $46.93 |
| Price | $47.04 | Change | 0.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$83.96
Mean price target
2. Current target
$46.55
Latest analyst target
3. DCF / Fair value
$-38.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$46.55
Low
$33.00
High
$291.00
Mean
$83.96
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | reit | Piper Sandler | Overweight → Overweight | $110 |
| 2026-02-17 | main | Chardan Capital | Buy → Buy | $76 |
| 2026-02-13 | main | TD Cowen | Hold → Hold | $45 |
| 2026-02-13 | main | Evercore ISI Group | Outperform → Outperform | $74 |
| 2026-02-13 | main | Needham | Buy → Buy | $82 |
| 2026-01-30 | main | Citizens | Market Outperform → Market Outperform | $80 |
| 2025-12-23 | reit | Needham | Buy → Buy | $80 |
| 2025-12-23 | reit | Citizens | Market Outperform → Market Outperform | $86 |
| 2025-11-26 | main | Chardan Capital | Buy → Buy | $74 |
| 2025-11-12 | main | Citigroup | Buy → Buy | $77 |
| 2025-11-11 | main | RBC Capital | Sector Perform → Sector Perform | $50 |
| 2025-11-11 | main | Baird | Neutral → Neutral | $44 |
| 2025-11-10 | main | Needham | Buy → Buy | $80 |
| 2025-10-17 | main | B of A Securities | Buy → Buy | $93 |
| 2025-10-10 | reit | Needham | Buy → Buy | $81 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-18 | init | JP Morgan | — → Overweight | $70 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-08-06 | main | Barclays | Equal-Weight → Equal-Weight | $56 |
| 2025-08-05 | main | Chardan Capital | Buy → Buy | $82 |
- Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool Wed, 04 Mar 2026 08
- $CRSP stock is up 3% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Mar 2026 19
- Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Yahoo Finance ue, 17 Mar 2026 14
- From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here - 24/7 Wall St. ue, 17 Mar 2026 16
- Is CRISPR Therapeutics Stock a Buy Now? - The Globe and Mail Fri, 20 Mar 2026 12
- CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan ue, 17 Mar 2026 21
- CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes Offering - Has The Bull Case Changed? - simplywall.st Wed, 18 Mar 2026 03
- CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat ue, 17 Mar 2026 22
- CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore hu, 19 Mar 2026 21
- Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat ue, 17 Mar 2026 22
- Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? - The Motley Fool Mon, 02 Mar 2026 08
- CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance hu, 15 Jan 2026 08
- This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday - The Motley Fool ue, 10 Mar 2026 07
- Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool ue, 17 Mar 2026 21
- CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada Wed, 18 Mar 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9869 | 476278.0 | — | Sale at price 48.26 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-03-16 00:00:00 | D |
| 1 | 3150 | 152019.0 | — | Sale at price 48.26 per share. | PATEL NAIMISH M.D. | Officer | — | 2026-03-16 00:00:00 | D |
| 2 | 10349 | 499443.0 | — | Sale at price 48.26 per share. | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-03-16 00:00:00 | D |
| 3 | 3450 | 166497.0 | — | Sale at price 48.26 per share. | KASINGER JAMES R. | General Counsel | — | 2026-03-16 00:00:00 | D |
| 4 | 750 | — | — | Stock Gift at price 0.00 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-03-16 00:00:00 | D |
| 5 | 6875 | nan | — | — | KASINGER JAMES R. | General Counsel | — | 2026-03-13 00:00:00 | D |
| 6 | 16875 | nan | — | — | PRASAD RAJU | Chief Financial Officer | — | 2026-03-13 00:00:00 | D |
| 7 | 8125 | nan | — | — | PATEL NAIMISH M.D. | Officer | — | 2026-03-13 00:00:00 | D |
| 8 | 20625 | nan | — | — | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-03-13 00:00:00 | D |
| 9 | 9798 | 517334.0 | — | Sale at price 52.80 per share. | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-03-11 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.09 | 0.09 | 0.09 | 0.00 |
| NormalizedEBITDA | -645.09M | -447.31M | -202.70M | -648.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -581.60M | -366.25M | -153.61M | -650.17M |
| ReconciledDepreciation | 19.48M | 19.26M | 19.84M | 24.17M |
| ReconciledCostOfRevenue | 213.48M | 120.67M | 130.25M | 110.25M |
| EBITDA | -645.09M | -447.31M | -202.70M | -648.99M |
| EBIT | -664.57M | -466.57M | -222.54M | -673.16M |
| NormalizedIncome | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -581.60M | -366.25M | -153.61M | -650.17M |
| TotalExpenses | 664.57M | 501.57M | 592.54M | 673.60M |
| TotalOperatingIncomeAsReported | -664.57M | -466.57M | -222.54M | -673.16M |
| DilutedAverageShares | 89.93M | 84.36M | 79.22M | 77.75M |
| BasicAverageShares | 89.93M | 84.36M | 79.22M | 77.75M |
| DilutedEPS | -6.47 | -4.34 | -1.94 | -8.36 |
| BasicEPS | -6.47 | -4.34 | -1.94 | -8.36 |
| DilutedNIAvailtoComStockholders | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeCommonStockholders | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncome | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeIncludingNoncontrollingInterests | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeContinuousOperations | -581.60M | -366.25M | -153.61M | -650.17M |
| TaxProvision | 3.63M | 3.59M | 2.89M | -325.00K |
| PretaxIncome | -577.97M | -362.67M | -150.72M | -650.50M |
| OtherIncomeExpense | 86.61M | 103.90M | 71.82M | 22.66M |
| OtherNonOperatingIncomeExpenses | 86.61M | 103.90M | 71.82M | 22.66M |
| OperatingIncome | -664.57M | -466.57M | -222.54M | -673.16M |
| OperatingExpense | 451.09M | 380.90M | 462.29M | 563.35M |
| OtherOperatingExpenses | -3.51M | -2.31M | -1.21M | -762.00K |
| ResearchAndDevelopment | 381.06M | 310.24M | 387.33M | 461.64M |
| SellingGeneralAndAdministration | 73.54M | 72.98M | 76.16M | 102.46M |
| GeneralAndAdministrativeExpense | 73.54M | 72.98M | 76.16M | 102.46M |
| OtherGandA | 73.54M | 72.98M | 76.16M | 102.46M |
| GrossProfit | -213.48M | -85.67M | 239.75M | -109.81M |
| CostOfRevenue | 213.48M | 120.67M | 130.25M | 110.25M |
| TotalRevenue | 0.00 | 35.00M | 370.00M | 436.00K |
| OperatingRevenue | 0.00 | 35.00M | 370.00M | 436.00K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 115.32K | 170.32K | 170.32K | 180.32K |
| OrdinarySharesNumber | 95.89M | 85.74M | 80.04M | 78.51M |
| ShareIssued | 96.01M | 85.91M | 80.21M | 78.69M |
| TotalDebt | 206.75M | 223.69M | 238.63M | 244.02M |
| TangibleBookValue | 1.92B | 1.93B | 1.88B | 1.88B |
| InvestedCapital | 1.92B | 1.93B | 1.88B | 1.88B |
| WorkingCapital | 1.84B | 1.85B | 1.80B | 1.73B |
| NetTangibleAssets | 1.92B | 1.93B | 1.88B | 1.88B |
| CapitalLeaseObligations | 206.75M | 223.69M | 238.63M | 244.02M |
| CommonStockEquity | 1.92B | 1.93B | 1.88B | 1.88B |
| TotalCapitalization | 1.92B | 1.93B | 1.88B | 1.88B |
| TotalEquityGrossMinorityInterest | 1.92B | 1.93B | 1.88B | 1.88B |
| StockholdersEquity | 1.92B | 1.93B | 1.88B | 1.88B |
| GainsLossesNotAffectingRetainedEarnings | 4.82M | 1.84M | 1.91M | -15.65M |
| OtherEquityAdjustments | 4.82M | 1.84M | 1.91M | -15.65M |
| TreasuryStock | 60.00K | 62.00K | 62.00K | 63.00K |
| RetainedEarnings | -1.95B | -1.37B | -999.70M | -846.09M |
| AdditionalPaidInCapital | 3.86B | 3.29B | 2.88B | 2.73B |
| CapitalStock | 3.09M | 2.70M | 2.50M | 2.44M |
| CommonStock | 3.09M | 2.70M | 2.50M | 2.44M |
| TotalLiabilitiesNetMinorityInterest | 343.43M | 309.95M | 346.77M | 367.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 194.31M | 222.17M | 237.98M | 246.47M |
| OtherNonCurrentLiabilities | 6.14M | 3.44M | 958.00K | 5.97M |
| NonCurrentDeferredLiabilities | 0.00 | 12.32M | 14.01M | 12.32M |
| NonCurrentDeferredRevenue | 0.00 | 12.32M | 14.01M | 12.32M |
| LongTermDebtAndCapitalLeaseObligation | 188.17M | 206.41M | 223.01M | 228.18M |
| LongTermCapitalLeaseObligation | 188.17M | 206.41M | 223.01M | 228.18M |
| CurrentLiabilities | 149.12M | 87.78M | 108.79M | 121.11M |
| OtherCurrentLiabilities | 13.11M | 10.42M | 5.14M | 20.00K |
| CurrentDeferredLiabilities | 15.77M | 3.85M | 4.11M | 0.00 |
| CurrentDeferredRevenue | 15.77M | 3.85M | 4.11M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 18.58M | 17.29M | 15.62M | 15.84M |
| CurrentCapitalLeaseObligation | 18.58M | 17.29M | 15.62M | 15.84M |
| PayablesAndAccruedExpenses | 101.66M | 56.23M | 83.92M | 105.25M |
| CurrentAccruedExpenses | 89.41M | 41.07M | 45.34M | 77.68M |
| Payables | 12.25M | 15.16M | 38.59M | 27.56M |
| TotalTaxPayable | 1.11M | 451.00K | 438.00K | 135.00K |
| AccountsPayable | 11.14M | 14.71M | 38.15M | 27.43M |
| TotalAssets | 2.27B | 2.24B | 2.23B | 2.24B |
| TotalNonCurrentAssets | 279.57M | 304.90M | 321.49M | 390.03M |
| OtherNonCurrentAssets | 32.00M | 27.35M | 13.57M | 16.27M |
| InvestmentsAndAdvances | 0.00 | 1.97M | 53.13M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 1.97M | 53.13M | 0.00 |
| AvailableForSaleSecurities | 1.97M | 53.13M | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 16.00K | 71.00K | 125.00K |
| NetPPE | 247.57M | 277.55M | 305.94M | 320.56M |
| AccumulatedDepreciation | -91.05M | -72.27M | -53.43M | -33.83M |
| GrossPPE | 338.63M | 349.83M | 359.37M | 354.39M |
| Leases | 146.67M | 145.85M | 143.26M | 141.68M |
| ConstructionInProgress | 3.96M | 6.12M | 8.86M | 6.16M |
| OtherProperties | 175.30M | 185.47M | 195.40M | 194.82M |
| MachineryFurnitureEquipment | 12.71M | 12.39M | 11.85M | 11.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.99B | 1.94B | 1.91B | 1.85B |
| OtherCurrentAssets | 9.84M | 8.31M | 14.39M | 37.71M |
| PrepaidAssets | 38.08M | |||
| Receivables | 0.00 | 25.00M | 200.00M | 0.00 |
| AccountsReceivable | 0.00 | 25.00M | 200.00M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 1.98B | 1.90B | 1.69B | 1.82B |
| OtherShortTermInvestments | 1.63B | 1.61B | 1.30B | 1.60B |
| CashAndCashEquivalents | 347.56M | 298.26M | 389.48M | 211.88M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -370.93M | -144.68M | -272.35M | -532.93M |
| IssuanceOfCapitalStock | 398.09M | 300.69M | 32.72M | 970.00K |
| CapitalExpenditure | -25.91M | -1.90M | -11.97M | -37.19M |
| EndCashPosition | 359.08M | 309.78M | 401.07M | 224.06M |
| BeginningCashPosition | 309.78M | 401.07M | 224.06M | 939.94M |
| EffectOfExchangeRateChanges | 95.00K | -21.00K | 73.00K | -80.00K |
| ChangesInCash | 49.21M | -91.27M | 176.94M | -715.80M |
| FinancingCashFlow | 426.03M | 331.98M | 62.66M | 38.59M |
| CashFlowFromContinuingFinancingActivities | 426.03M | 331.98M | 62.66M | 38.59M |
| ProceedsFromStockOptionExercised | 27.94M | 31.29M | 29.94M | 37.62M |
| NetCommonStockIssuance | 398.09M | 300.69M | 32.72M | 970.00K |
| CommonStockIssuance | 398.09M | 300.69M | 32.72M | 970.00K |
| InvestingCashFlow | -31.80M | -280.48M | 374.65M | -258.65M |
| CashFlowFromContinuingInvestingActivities | -31.80M | -280.48M | 374.65M | -258.65M |
| NetInvestmentPurchaseAndSale | -5.89M | -278.58M | 386.62M | -221.47M |
| SaleOfInvestment | 1.01B | 1.21B | 1.45B | 1.20B |
| PurchaseOfInvestment | -1.02B | -1.49B | -1.07B | -1.42B |
| NetIntangiblesPurchaseAndSale | -25.00M | 0.00 | -2.50M | 0.00 |
| PurchaseOfIntangibles | -25.00M | 0.00 | -2.50M | 0.00 |
| NetPPEPurchaseAndSale | -914.00K | -1.90M | -9.47M | -37.19M |
| PurchaseOfPPE | -914.00K | -1.90M | -9.47M | -37.19M |
| OperatingCashFlow | -345.01M | -142.77M | -260.38M | -495.74M |
| CashFlowFromContinuingOperatingActivities | -345.01M | -142.77M | -260.38M | -495.74M |
| ChangeInWorkingCapital | 71.88M | 156.27M | -193.59M | 19.84M |
| ChangeInOtherWorkingCapital | -5.61M | -6.36M | 3.33M | 14.30M |
| ChangeInOtherCurrentLiabilities | 4.26M | 9.62M | 110.00K | -1.52M |
| ChangeInPayablesAndAccruedExpense | 44.89M | -27.28M | -20.25M | 5.16M |
| ChangeInPrepaidAssets | 3.34M | 5.29M | 23.22M | 1.60M |
| ChangeInReceivables | 25.00M | 175.00M | -200.00M | 305.00K |
| ChangesInAccountReceivables | 25.00M | 175.00M | -200.00M | 305.00K |
| OtherNonCashItems | 72.72M | -38.62M | -14.04M | 12.47M |
| StockBasedCompensation | 72.50M | 86.57M | 81.03M | 97.95M |
| AmortizationOfSecurities | 14.11M | |||
| DepreciationAmortizationDepletion | 19.48M | 19.26M | 19.84M | 24.17M |
| DepreciationAndAmortization | 19.48M | 19.26M | 19.84M | 24.17M |
| Depreciation | 19.40M | 19.20M | ||
| EarningsLossesFromEquityInvestments | 0.00 | |||
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -581.60M | -366.25M | -153.61M | -650.17M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRSP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|